Vitamin E Level in Buccal Cells of Arsenicosis Patients
NCT ID: NCT01743066
Last Updated: 2012-12-06
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
60 participants
INTERVENTIONAL
2010-10-31
2011-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
PARALLEL
BASIC_SCIENCE
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Arsenicosis patients
Vitamin E (200 IU, caplet) daily orally for 20 weeks
Vitamin E
vitamin E (200 IU, caplet) daily orally for 20 weeks
Arsenic exposed controls
vitamin E (200 IU, caplet) daily orally for 20 weeks
Vitamin E
vitamin E (200 IU, caplet) daily orally for 20 weeks
Heathy volunteers
Vitamin E (200 IU, caplet) daily orally for 20 weeks
Vitamin E
vitamin E (200 IU, caplet) daily orally for 20 weeks
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Vitamin E
vitamin E (200 IU, caplet) daily orally for 20 weeks
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* who drank arsenic contaminated water (\>50 µg/L) for more than 6 months
* having physical signs of moderate degree of melanosis and keratosis
For arsenic exposed control
* relative or family member of the patient
* showing no physical signs of melanosis and keratosis
* share same tube well water for drinking purpose for more than 6 months
For healthy volunteers
* who drank arsenic safe water (\<50 µg/L)
* live in the same Upazilla
* have no cutaneous manifestation
* who voluntarily agree to participate
Exclusion Criteria
* patients getting treatment of arsenicosis
* subject who voluntarily do not agree to participate
18 Years
70 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Prof. Mir Misbahuddin
Prof. and Chairman
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Department of Pharmacology, Bangabandhu Sheikh Mujib Medical University
Dhaka, , Bangladesh
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
BSMMU-004-CT
Identifier Type: -
Identifier Source: org_study_id